Low-Dose Tadalafil and Cabergoline versus Cabergoline alone in Management of Erectile Dysfunction in Patients with End-Stage Renal Disease and Hyperprolactinemia Undergoing Hemodialysis
Abd ElMaqsood, A., Salih, E., Elsalhy, M., Ayoub, H. (2025). Low-Dose Tadalafil and Cabergoline versus Cabergoline alone in Management of Erectile Dysfunction in Patients with End-Stage Renal Disease and Hyperprolactinemia Undergoing Hemodialysis. EKB Journal Management System, 2025(4), 227-231. doi: 10.21608/aimj.2025.446529
Ali Sobhi Ali Abd ElMaqsood; Elsayed Mohammed Salih; Mohammed Abd Elrahim Elsalhy; Hazem Sayed Ahmed Ayoub. "Low-Dose Tadalafil and Cabergoline versus Cabergoline alone in Management of Erectile Dysfunction in Patients with End-Stage Renal Disease and Hyperprolactinemia Undergoing Hemodialysis". EKB Journal Management System, 2025, 4, 2025, 227-231. doi: 10.21608/aimj.2025.446529
Abd ElMaqsood, A., Salih, E., Elsalhy, M., Ayoub, H. (2025). 'Low-Dose Tadalafil and Cabergoline versus Cabergoline alone in Management of Erectile Dysfunction in Patients with End-Stage Renal Disease and Hyperprolactinemia Undergoing Hemodialysis', EKB Journal Management System, 2025(4), pp. 227-231. doi: 10.21608/aimj.2025.446529
Abd ElMaqsood, A., Salih, E., Elsalhy, M., Ayoub, H. Low-Dose Tadalafil and Cabergoline versus Cabergoline alone in Management of Erectile Dysfunction in Patients with End-Stage Renal Disease and Hyperprolactinemia Undergoing Hemodialysis. EKB Journal Management System, 2025; 2025(4): 227-231. doi: 10.21608/aimj.2025.446529

Low-Dose Tadalafil and Cabergoline versus Cabergoline alone in Management of Erectile Dysfunction in Patients with End-Stage Renal Disease and Hyperprolactinemia Undergoing Hemodialysis

Al-Azhar International Medical Journal
Volume 2025, Issue 4, April 2025, Page 227-231  XML PDF (373.99 K)
Document Type: Original Article
DOI: 10.21608/aimj.2025.446529
View on SCiNiTO View on SCiNiTO
Authors
Ali Sobhi Ali Abd ElMaqsood1; Elsayed Mohammed Salih1; Mohammed Abd Elrahim Elsalhy1; Hazem Sayed Ahmed Ayoub2
1Urology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
2Nephrology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
Abstract
Background: Hyperprolactinemia in chronic kidney disease (CKD) is associated with high rates of hypogonadism and erectile dysfunction (ED). This study compares the efficacy, safety, and side effects of cabergoline monotherapy versus low-dose tadalafil combined with cabergoline in treating ED in end-stage renal disease (ESRD) patients undergoing hemodialysis with hyperprolactinemia.
Patients and Methods: A total of 120 male ESRD patients on hemodialysis with ED and hyperprolactinemia were enrolled from November 2023 to December 2024 at Al-Azhar Hemodialysis Units, Cairo, Egypt. Patients were randomly assigned to two groups: Group 1 received 0.5 mg of cabergoline weekly, while Group 2 received 5 mg of tadalafil daily along with 0.5 mg of cabergoline. Efficacy was assessed using the International Index of Erectile Function-5 (IIEF-5) and hormonal assays for prolactin and testosterone after 6 weeks of treatment.
Results: The combined Cabergoline/Tadalafil group showed a significant improvement in IIEF-5 scores (from 14.79 to 22.8, P<0.001), whereas the Cabergoline-only group showed no significant change. Prolactin levels decreased significantly in both groups (P<0.05), with no significant change in testosterone levels. Side effects were more common in the combined Cabergoline/Tadalafil group: 35% had back pain, 8.3% dizziness, and 48.3% headaches, compared to 11.6%, 1.7%, and 11.7%, respectively, in the Cabergoline-only group (P<0.05).
Conclusion: Low-dose tadalafil combined with cabergoline is a promising treatment for ED and hyperprolactinemia in ESRD patients. Although side effects were more common, most were mild and self-limited.
Keywords
Cabergoline; Erectile dysfunction; Hemodialysis; Hyperprolactinemia; Tadalafil
Statistics
Article View: 1